Journals / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 1

Medical treatment of gastroesophageal reflux disease

Pages
48–52
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In patients who use PPIs for a long time, the drug must be stopped by gradually decreasing the dose

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Proton pump inhibitors (PPIs) are the most effective agents in the first-line and maintenance treatment of gastroesophageal reflux disease.
📊
Key Findings & Data:As the grade of esophagitis increases, an increase is also observed in the level of endoscopic response to PPIs.
💡
Conclusion & Impact:In patients who use PPIs for a long time, the drug must be stopped by gradually decreasing the dose
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Proton pump inhibitors (PPIs) are the most effective agents in the first-line and maintenance treatment of gastroesophageal reflux disease. As the grade of esophagitis increases, an increase is also observed in the level of endoscopic response to PPIs. In the first-line therapy of patients with severe esophagitis (Los Angeles (LA) Grade C-D), administration of a standard dose of PPIs bid has been reported to be more beneficial than PPIs qd. While any intermittant and low dose-continuous treatment can be chosen for the maintenance therapy of patients with non-erosive reflux disease or mild esophagitis (LA Grade A-B), continuous use of a standard dose of PPIs is preferred in the maintenance therapy of patients with severe esophagitis (LA Grade C-D). In patients who use PPIs for a long time, the drug must be stopped by gradually decreasing the dose

🔖

Cite This Article

BOR, S., KALKAN, İ. H. (2017). Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 1, 48–52. https://ajindex.com/articles/410216

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095
  2. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 1419-25. [CrossRef] 3. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003; 17: 1237-45. [CrossRef] 4. Edwards SJ, Lind T, Lundell L, DAS R. Systematic review: standardand double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547-56. [CrossRef] 5. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus otherproton pump inhibitors in erosive esophagitis: a metaanalysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006; 4: 1452-8. [CrossRef] 6. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-21. [CrossRef] 7. Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W; Pantoprazole US GERD Study Group. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004; 20: 567-75. [CrossRef] 8. Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Doubledosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol 2010; 105: 1046-52. [CrossRef] 9. Scott M, Gelhot AR. Gastroesophageal reflux disease,diagnosis and management. Am Fam Physician 1999; 59: 1161-9
  3. Williams LN. Gastroesophageal reflux disease. Canadian J Gastroenterology 1997; 92(Suppl 4): 22s-7s
  4. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; CD003245
  5. Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig 2007; 27: 287-96. [CrossRef] 1